| Market Capitalization (Millions $) |
651 |
| Shares
Outstanding (Millions) |
34 |
| Employees |
434 |
| Revenues (TTM) (Millions $) |
267 |
| Net Income (TTM) (Millions $) |
-213 |
| Cash Flow (TTM) (Millions $) |
451 |
| Capital Exp. (TTM) (Millions $) |
0 |
Morphosys Ag
Morphosys AG is a German biotechnology company focused on the development of therapeutic antibodies for the treatment of cancer and other diseases. Founded in 1992, the company has its headquarters in Planegg near Munich in Germany.
Morphosys AG's core technology is based on its proprietary antibody platform called "HuCAL" (Human Combinatorial Antibody Library). This technology enables the generation of fully human monoclonal antibodies that can target specific disease targets with high affinity and specificity. The antibodies can be optimized for different applications, such as cancer treatment or autoimmune diseases, using its proprietary "Ylanthia" antibody library.
Morphosys has a strong pipeline of therapeutic antibodies in various phases of development. Its lead product candidate, MOR208, is a monoclonal antibody targeting CD19, a protein expressed on the surface of B cells. The drug is currently in phase 3 clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), one of the most common types of non-Hodgkin's lymphoma. Another drug candidate, MOR202, targets CD38, a protein found on the surface of multiple myeloma cells. The drug is currently in phase 2 clinical trials.
Morphosys has partnerships with several major pharmaceutical companies, including Johnson & Johnson, Bayer AG, Novartis AG, and Roche Holding AG. These partnerships provide the company with access to funding, expertise, and technology, as well as the potential for future milestone payments and royalties.
Morphosys has a global presence, with offices and research facilities in the United States, Japan, and Europe. The company has a strong commitment to corporate social responsibility, with initiatives focused on sustainability, patient welfare, and diversity and inclusion.
In summary, Morphosys AG is a leading biotechnology company focused on the development of therapeutic antibodies for the treatment of cancer and other diseases. The company's proprietary technology, strong pipeline, and partnerships with major pharmaceutical companies position it well for future growth and success in the biotech industry.
Company Address: Semmelweisstrasse 7 Planegg 82152
Company Phone Number: 89-89927-0 Stock Exchange / Ticker: NASDAQ MOR
|
